Short answer
BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.01 (Changes in Control of Registrant), Item 5.07 (Submission of Matters to a Vote of Security Holders). Acquisition completed, with each BioLife share converted into 0.1442 Repligen shares plus $11.25 cash.
- This filing includes Item 3.01, an item that often signal trouble.
BIOLIFE SOLUTIONS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Acquisition completed, with each BioLife share converted into 0.1442 Repligen shares plus $11.25 cash
- Transaction consideration combines equity participation with immediate cash value for BioLife shareholders
- No fractional Repligen shares issued, with cash paid for fractional interests
- Employee options and equity awards accelerated, vested, and converted into merger consideration
- BioLife shareholders with perfected appraisal rights excluded from standard merger consideration
Item 3.01 · Notice of Delisting
- BioLife ceased as a separate legal entity following the Mergers, eliminating its Nasdaq listing eligibility
- Nasdaq trading halted after the October 5, 2026 after-market session
- BioLife Common Stock delisted from Nasdaq following merger closing on October 6, 2026
- Planned Form 15 filing would terminate SEC registration and suspend ongoing reporting obligations
- BLFS shareholders should expect no further public-company periodic reports after the merger close
Item 3.03 · Material Modification to Rights of Security Holders
- First merger completed, ending existing BioLife common stockholder rights
- Non-dissenting holders entitled only to merger consideration for their shares
- Dissenting holders limited to appraisal rights under Delaware law
- Transaction also triggers reported acquisition, delisting and governance changes under Items 2.01, 3.01 and 5.03
Item 5.01 · Changes in Control of Registrant
- Completed mergers triggered a change in control of BioLife Solutions
- BioLife became a wholly owned subsidiary of Repligen
- Transaction removes BioLife as an independent public company, shifting shareholder exposure to Repligen
Item 5.02 · Departure/Election of Directors or Officers
- Merger-driven replacement of BioLife’s entire seven-member board, eliminating the pre-transaction governance team
- Merger Sub 1 directors and officers assumed BioLife leadership roles at the First Merger Effective Time
- All five named executive officers resigned, creating complete executive turnover and material execution risk
- Investors should reassess governance, strategy, integration accountability and leadership continuity following the merger
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Merger-triggered restatement of BioLife’s certificate of incorporation and bylaws effective at the First Merger Effective Time
- Governance documents replaced in full, signaling post-merger changes to corporate structure and shareholder rights
- Investors should review Exhibits 3.1 and 3.2 for voting, board, and other governance changes
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Merger Agreement adopted, clearing the key shareholder approval needed for Repligen’s acquisition of BioLife
- Proposal 1 received 40,910,337 votes for versus 83,451 against, an overwhelming approval margin
- Meeting quorum established with 40,994,595 shares, representing 83.79% of eligible shares
- Merger-related executive compensation approved on a non-binding basis, with 35,037,565 votes for
- Adjournment proposal became moot because sufficient votes already supported the merger agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOLIFE SOLUTIONS INC 8-K filings
Get the next BLFS 8-K as it lands
Follow BLFS for push alerts, or ask the research agent what this filing means.